Nov. 30, 2023 7:51 am ET
AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company’s entry into the commercial market for ovarian cancer.
AbbVie on Thursday said it will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday’s closing price of $16.06 for the Waltham, Mass., pharmaceutical company.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Source: finance.yahoo.com
Related posts:
U.S. natural gas is trading at an ‘insane’ price — Here’s why it just hit a nearly 14-year high
The SALT Cap Has a $20 Billion Hole
Jamie Dimon Calls Fitch Downgrade ‘Ridiculous’
‘Get out of these distorted markets’: Mohamed El-Erian issues a dire warning to stock and bond inves...
India arrests two senior employees of Chinese firm Vivo - source